Dr. Mamounas on Adjuvant Endocrine Therapy for Breast Cancer

Eleftherios (Terry) P. Mamounas, MD
Published: Thursday, Aug 31, 2017



Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.

For years, many thought that 5 years of tamoxifen was the standard, states Mamounas. Studies had shown that additional therapy to around 10 years did not show any improvement.

However, with 15 years of follow-up, there has been a benefit in disease-free survival in patients receiving 10 years of tamoxifen, explains Mamounas.

SELECTED
LANGUAGE


Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.

For years, many thought that 5 years of tamoxifen was the standard, states Mamounas. Studies had shown that additional therapy to around 10 years did not show any improvement.

However, with 15 years of follow-up, there has been a benefit in disease-free survival in patients receiving 10 years of tamoxifen, explains Mamounas.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x